FDA turns down Perth medtech

17/06/2022 - 11:05

Bookmark

Upgrade your subscription to use this feature.

Artrya shares continued to drop this morning after the US Food and Drug Administration knocked back its AI-based coronary diagnostic product for commercial use.

Subscribe to read this article.

Register or login now and receive unlimited access to our award-winning, unbiased and trusted
journalism. Your key to local business, news, insights and data.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options